Form 4: BSX Director Morano Receives Restricted Stock Grant

Boston Scientific Director Susan E. Morano received a grant of 24 restricted common shares as part of her compensation, vesting at the next annual meeting.

Summary

• Susan E. Morano, a Director of Boston Scientific Corp (BSX), acquired 24 shares of common stock.
• The transaction occurred on March 2, 2026, and was an acquisition (A) of securities.
• The shares were granted as restricted stock in lieu of 50% of cash compensation.
• The grant reflects a value of $1,845.25, calculated by dividing this value by the closing price of common stock on the grant date.
• The restricted stock will vest in full upon the next annual meeting of stockholders.
• Following this transaction, Ms. Morano beneficially owns 6,663 shares of common stock directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive, routine event. While not a major market mover, it reflects standard corporate governance practices and aligns director interests with shareholders, which is generally favorable.

Positives

• The grant of restricted stock aligns the interests of Director Susan E. Morano with those of Boston Scientific shareholders, as her compensation is tied to the company's equity performance.
• This form of compensation is a common practice for non-employee directors, promoting long-term commitment and stewardship.

Future Outlook

The 24 restricted shares granted to Director Morano are scheduled to vest in full upon the company's next annual meeting of stockholders, indicating a future event for the realization of this compensation.

Industry Context

StockSavvy.ai notes that the practice of compensating non-employee directors with equity, such as restricted stock, is a widespread corporate governance trend across various industries, including medical technology. This approach is designed to align the financial interests of directors with the long-term performance of the company and its shareholders.

Comparison to Industry Standards

• The grant of restricted stock as part of director compensation is a standard practice observed in many large-cap companies, including peers in the medical device sector such as Medtronic (MDT) and Abbott Laboratories (ABT), which also utilize equity-based awards to incentivize their board members.
• The specific value and number of shares granted are typically determined by a company's compensation committee based on market benchmarks for director compensation, company size, and performance.

Related Party Transactions

• The grant of restricted stock to Director Susan E. Morano constitutes a related party transaction, as it is compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with shareholder value creation, potentially encouraging decisions that benefit long-term stock performance.
• Employees: No direct impact on employees is indicated by this specific filing.

Next Steps

• The restricted stock will vest in full upon the next annual meeting of stockholders.

Key Dates

Recommendation

This Form 4 filing details a routine compensation grant to a director and does not contain information significant enough to alter an investment thesis for Boston Scientific. The transaction is expected and aligns director interests, but it is not a catalyst for a 'buy' or 'sell' recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals and market conditions.

Keywords

Boston Scientific, BSX, Form 4, Insider Transaction, Restricted Stock, Director Compensation, Equity Grant, Corporate Governance